Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,667 · see citing works

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents

Esteller, M., García‐Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,256 · see citing works

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells

Ebert, M. S., Neilson, J. R., & Sharp, P. A. (2007) · Nature Methods · doi:10.1038/nmeth1079 · Cited by 1,845 · see citing works

Human DNA Repair Genes

Wood, R., Mitchell, M., Sgouros, J., & Lindahl, T. (2001) · Science · doi:10.1126/science.1056154 · Cited by 1,719 · see citing works

Galectins as modulators of tumour progression

Liu, F., & Rabinovich, G. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1527 · Cited by 1,435 · see citing works

Control of apoptosis by p53

Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401 · see citing works

Monoclonal antibodies: versatile platforms for cancer immunotherapy

Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature reviews. Immunology · doi:10.1038/nri2744 · Cited by 1,282 · see citing works

Balancing repair and tolerance of DNA damage caused by alkylating agents

Fu, D., Calvo, J. A., & Samson, L. D. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3185 · Cited by 946 · see citing works

Regulation of PTEN Transcription by p53

Stambolic, V., MacPherson, D. P., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., & Mak, T. W. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00323-9 · Cited by 913 · see citing works

Galectin-1: a small protein with major functions

Camby, I., Mercier, M. L., Lefranc, F., & Robert Kiss, A. (2006) · Glycobiology · doi:10.1093/glycob/cwl025 · Cited by 892 · see citing works

Temozolomide: Mechanisms of Action, Repair and Resistance

Zhang, J., Stevens, M. F. G., & Bradshaw, T. D. (2011) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 887 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Temozolomide and treatment of malignant glioma.

Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · Cited by 722 · see citing works

MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

Kaina, B., Christmann, M., Naumann, S. C., & Roos, W. P. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 662 · see citing works

Alkylation damage in DNA and RNA—repair mechanisms and medical significance

Drabløs, F., Feyzi, E., Aas, P. A., Vågbø, C. B., Kavli, B., Bratlie, M. S., Peña-Dı́az, J., Otterlei, M., Slupphaug, G., & Krokan, H. E. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.05.004 · Cited by 645 · see citing works

Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991) · PubMed · Cited by 630 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

Functions of the MDM2 oncoprotein

Freedman, D. A., Wu, L., & Levine, A. J. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050273 · Cited by 573 · see citing works

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection

Rubinstein, N., Alvarez, M. J., Zwirner, N. W., Toscano, M. A., Ilarregui, J. M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O. L., & Rabinovich, G. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00024-8 · Cited by 529 · see citing works

Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?

Rabinovich, G. A., Baum, L. G., Tinari, N., Paganelli, R., Natoli, C., Liu, F., & Iacobelli, S. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02232-9 · Cited by 527 · see citing works

PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms

Freeman, D. J., Li, A. G., Wei, G., Li, H.-H., Kertesz, N. L., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00021-7 · Cited by 512 · see citing works

NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNA

Denny, B. J., Wheelhouse, R. T., Stevens, M. F. G., Tsang, L. L. H., & Slack, J. A. (1994) · Biochemistry · doi:10.1021/bi00197a003 · Cited by 442 · see citing works

A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification

Almeida, K. H., & Sobol, R. W. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.01.009 · Cited by 437 · see citing works

MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance

Yip, S. S. F., Miao, J., Cahill, D. P., Iafrate, A. J., Aldape, K., Nutt, C. L., & Louis, D. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3012 · Cited by 403 · see citing works

Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation

Paz, A., Haklai, R., Elad‐Sfadia, G., Ballan, E., & Kloog, Y. (2001) · Oncogene · doi:10.1038/sj.onc.1204950 · Cited by 400 · see citing works

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Prados, M. D., Chang, S. M., Butowski, N. A., DeBoer, R. J., Parvataneni, R., Carliner, H., Kabuubi, P., Ayers-Ringler, J. R., Rabbitt, J. E., Page, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9639 · Cited by 378 · see citing works

Oncogenic EGFR Signaling Networks in Glioma

Huang, P. H., Xu, A. M., & White, F. M. (2009) · Science Signaling · doi:10.1126/scisignal.287re6 · Cited by 359 · see citing works

PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy

Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108302200 · Cited by 351 · see citing works

MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity

Shi, L., Chen, J., Yang, J., Pan, T., Zhang, S., & Wang, Z. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.009 · Cited by 340 · see citing works

Proliferation of human malignant astrocytomas is dependent on Ras activation

Guha, A., Feldkamp, M. M., Lau, N. C., Boss, G. R., & Pawson, A. J. (1997) · Oncogene · doi:10.1038/sj.onc.1201455 · Cited by 337 · see citing works

Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177

Brown, P. D., Krishnan, S., Sarkaria, J. N., Wu, W., Jaeckle, K. A., Uhm, J. H., Geoffroy, F. J., Arusell, R. M., Kitange, G. J., Jenkins, R. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0612 · Cited by 275 · see citing works

The role of poly(ADP-ribose) in the DNA damage signaling network

Malanga, M., & Althaus, F. R. (2005) · Biochemistry and Cell Biology · doi:10.1139/o05-038 · Cited by 274 · see citing works

Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege

Le, Q., Shi, G., Cao, H., Nelson, D. W., Wang, Y., Chen, E. Y., Zhao, S., Kong, C. S., Richardson, D. L., O'Byrne, K. J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.0206 · Cited by 260 · see citing works

Inhibition of microRNA with antisense oligonucleotides

Esau, C. (2007) · Methods · doi:10.1016/j.ymeth.2007.11.001 · Cited by 258 · see citing works

Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo

Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256 · see citing works

Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma

Neyns, B., Sadones, J., Joosens, E. J., Bouttens, F., Verbeke, L., Baurain, J., D'Hondt, L. A., Strauven, T., Chaskis, C., Veld, P. I. '., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp032 · Cited by 250 · see citing works

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

Hong, B., van den Heuvel, A. P. J., Prabhu, V. V., Zhang, S., & El‐Deiry, W. S. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106101412 · Cited by 245 · see citing works

Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI

Yang, Y.-P., Chien, Y., Chiou, G., Cherng, J., Wang, M., Lo, W., Chang, Y.-L., Huang, P., Chen, Y., Shih, Y., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.071 · Cited by 238 · see citing works

Proautophagic Drugs: A Novel Means to Combat Apoptosis-Resistant Cancers, with a Special Emphasis on Glioblastomas

Lefranc, F., Facchini, V., & Kiss, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1395 · Cited by 237 · see citing works

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

Liu, L., Markowitz, S. D., & Gerson, S. L. (1996) · PubMed · Cited by 235 · see citing works

miR-195, miR-455-3p and miR-10a∗ are implicated in acquired temozolomide resistance in glioblastoma multiforme cells

Ujifuku, K., Mitsutake, N., Takakura, S., Matsuse, M., Saenko, V., Suzuki, K., Hayashi, K., Matsuo, T., Kamada, K., Nagata, I., et al. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.04.013 · Cited by 226 · see citing works

The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis

Babashah, S., & Soleimani, M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.02.008 · Cited by 215 · see citing works

Pten signaling in gliomas

Knobbe-Thomsen, C. B., Merlo, A. U., & Reifenberger, G. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.3.196 · Cited by 203 · see citing works

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074

Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., James, C. D., Scheithauer, B. W., Behrens, R. J., Flynn, P. J., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.070 · Cited by 191 · see citing works

Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.

Narita, Y., Nagane, M., Mishima, K., Huang, H.-J. S., Furnari, F. B., & Cavenee, W. K. (2002) · PubMed · Cited by 189 · see citing works

RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients

Chakravarti, A., Wang, M., Robins, H. I., Lautenschlaeger, T., Curran, W. J., Brachman, D. G., Schultz, C. J., Choucair, A. K., Dolled-Filhart, M. P., Christiansen, J., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.10.008 · Cited by 179 · see citing works

DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy

Tubbs, J. L., Pegg, A. E., & Tainer, J. A. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.03.011 · Cited by 175 · see citing works

Degradation of the alkylated form of the DNA repair protein, O6-alkylguanine-DNA alkyltransferase

Xu‐Welliver, M. (2002) · Carcinogenesis · doi:10.1093/carcin/23.5.823 · Cited by 168 · see citing works

EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance

Lo, H. (2010) · Current Molecular Pharmacology · doi:10.2174/1874467211003010037 · Cited by 162 · see citing works

Ras is involved in the negative control of autophagy through the class I PI3-kinase

Furuta, S., Hidaka, E., Ogata, A., Yokota, S., & Kamata, T. (2004) · Oncogene · doi:10.1038/sj.onc.1207539 · Cited by 158 · see citing works

Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

Kaina, B., Margison, G. P., & Christmann, M. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0491-7 · Cited by 150 · see citing works

Pten signaling in gliomas

Knobbe-Thomsen, C. B. (2002) · Neuro-Oncology · doi:10.1215/15228517-4-3-196 · Cited by 146 · see citing works

Present and potential future issues in glioblastoma treatment

Lefranc, F., Sadeghi, N., Camby, I., Metens, T., Dewitte, O., & Robert Kiss, A. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.719 · Cited by 139 · see citing works

O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy

Verbeek, B., Southgate, T. D., Gilham, D. E., & Margison, G. P. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldm036 · Cited by 138 · see citing works

Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments

Brandes, A. A., Franceschi, E., Tosoni, A., Hegi, M. E., & Stupp, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1810 · Cited by 135 · see citing works

Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis

Rabinovich, G. A., Cumashi, A., Bianco, G. A., Ciavardelli, D., Iurisci, I., DʼEgidio, M., Piccolo, E., Tinari, N., Nifantiev, N. E., & Iacobelli, S. (2005) · Glycobiology · doi:10.1093/glycob/cwj056 · Cited by 124 · see citing works

Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors.

Burton, E., Lamborn, K. R., Forsyth, P. A., Scott, J. N., O’Campo, J., Uyehara‐Lock, J. H., Prados, M. D., Berger, M. S., Passe, S. M., Uhm, J. H., et al. (2002) · PubMed · Cited by 121 · see citing works

Oncogenic role of microRNAs in brain tumors

Pang, J. C., Kwok, W. K., Chen, Z., & Ng, H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0525-0 · Cited by 120 · see citing works

O6-Methylguanine-DNA methyltransferase in glioma therapy: Promise and problems

Silber, J. R., Bobola, M. S., Blank, A., & Chamberlain, M. C. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.12.004 · Cited by 115 · see citing works

Galectins and Gliomas

Mercier, M. L., Ensign, S. P. F., Mathieu, V., Robert Kiss, A., & Lefranc, F. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00270.x · Cited by 110 · see citing works

Evidence of galectin-1 involvement in glioma chemoresistance☆

Mercier, M. L., Lefranc, F., Mijatovic, T., Debeir, O., Haibe‐Kains, B., Bontempi, G., Decaestecker, C., Robert Kiss, A., & Mathieu, V. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.01.009 · Cited by 106 · see citing works

MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells

Tanaka, M., Koul, D., Davies, M. A., Liebert, M., Steck, P. A., & Grossman, H. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203918 · Cited by 103 · see citing works

Functional evaluation of p53 and PTEN gene mutations in gliomas.

Kato, H., Kato, S., Kumabe, T., Sonoda, Y., Yoshimoto, T., Kato, S., Han, S., Suzuki, T., Shibata, H., Kanamaru, R., et al. (2000) · PubMed · Cited by 98 · see citing works

Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) – phase I/II trial: study protocol

Combs, S. E., Heeger, S., Haselmann, R., Edler, L., Debus, J., & Schulz–Ertner, D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-133 · Cited by 95 · see citing works

The -galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain

Miller, M. C., Klyosov, A. A., & Mayo, K. H. (2009) · Glycobiology · doi:10.1093/glycob/cwp084 · Cited by 91 · see citing works

Review of Mammalian DNA Repair and Translational Implications

Hansen, W. K., & Kelley, M. R. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38861-5 · Cited by 77 · see citing works

CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration

Bhakat, K. K., & Mitra, S. R. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg086 · Cited by 65 · see citing works

Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency

HORTON, J., & Wilson, S. H. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.10.016 · Cited by 61 · see citing works

The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas

Park, C., Kim, J., Kim, J. Y., Song, S. W., Kim, J. W., Choi, S. H., Kim, T. M., Lee, S., Kim, I. H., & Park, S. (2012) · Translational Oncology · doi:10.1593/tlo.12253 · Cited by 59 · see citing works

Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern

Camby, I., Decaestecker, C., Lefranc, F., Kaltner, H., Gabius, H., & Robert Kiss, A. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.037 · Cited by 55 · see citing works

Clinical implications of microRNAs in human glioblastoma

Mizoguchi, M., Guan, Y., Yoshimoto, K., Hata, N., Amano, T., Nakamizo, A., & Sasaki, T. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00019 · Cited by 55 · see citing works

Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy

Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 48 · see citing works

DAVANAT®(GM-CT-01) and Colon Cancer: Preclinical and Clinical (Phase I and II) Studies

Klyosov, A. A., Zomer, E., & Platt, D. (2012) · ACS symposium series · doi:10.1021/bk-2012-1102.ch004 · Cited by 33 · see citing works

Galectin-1 and immunotherapy for brain cancer

Verschuere, T., Vleeschouwer, S. D., Lefranc, F., Robert Kiss, A., & Gool, S. V. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.40 · Cited by 25 · see citing works

Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of O6-Methylguanine-DNA-methyltransferase, DNA Mismatch Repair, and p53

Pletsas, D., Garelnabi, E. A. E., Li, L., Phillips, R. M., & Wheelhouse, R. T. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401121k · Cited by 24 · see citing works

Synergistic cytotoxicity of the poly ( ADP ‐ribose) polymerase inhibitor ABT ‐888 and temozolomide in dual‐drug targeted magnetic nanoparticles

Muñoz‐Gámez, J. A., López-Viota, M., Barrientos, A., Carazo, Á., Sanjuán‐Nuñez, L., Quiles, R., Muñoz‐de‐Rueda, P., Delgado, Á. V., Ruiz‐Extremera, A., & Salmerón, J. (2014) · Liver International · doi:10.1111/liv.12586 · Cited by 14 · see citing works

Expression and significance of P53 protein and MDM-2 protein in human gliomas.

Wang, A.-L., Liu, Z., Li, G., & Zhang, L. (2011) · PubMed · Cited by 14 · see citing works

[Treatment of recurrent malignant gliomas by surgery combined with recombinant adenovirus-p53 injection].

Zhu, J., Li, Z., Geng, F.-Y., Fu, Q., Guo, C.-J., Xiao, Y.-L., Zhang, Z., & Li, G. (2010) · PubMed · Cited by 8 · see citing works

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 408 · see citing works

New insights into long noncoding RNAs and their roles in glioma

Peng, Z., Liu, C., & Wu, M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0812-2 · Cited by 379 · see citing works

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Jiapaer, S., Furuta, T., Tanaka, S., Kitabayashi, T., & Nakada, M. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2018-0141 · Cited by 325 · see citing works

Targeting autophagy to sensitive glioma to temozolomide treatment

Yan, Y., Xu, Z., Dai, S., Qian, L., Sun, L., & Gong, Z. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0303-5 · Cited by 298 · see citing works

Tumor Cell Infiltration into the Brain in Glioblastoma: From Mechanisms to Clinical Perspectives

Seker-Polat, F., Degirmenci, N. P., Solaroğlu, İ., & Onder, T. B. (2022) · Cancers · doi:10.3390/cancers14020443 · Cited by 261 · see citing works

Radiomics strategy for glioma grading using texture features from multiparametric MRI

Tian, Q., Yan, L., Zhang, X., Zhang, X., Hu, Y., Han, Y., Liu, Z., Nan, H., Sun, Q., Sun, Y., et al. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26010 · Cited by 214 · see citing works

Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma

Lun, X., Wells, J. C., Grinshtein, N., King, J. C., Hao, X., Dang, N.-H., Wang, X., Aman, A., Uehling, D., Datti, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1798 · Cited by 197 · see citing works

Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications

Ortíz, R., Perazzoli, G., Cabeza, L., Jiménez‐Luna, C., Luque, R., Prados, J. C., & Melguizo, C. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200626204005 · Cited by 178 · see citing works

MicroRNA in Glioblastoma: An Overview

Banelli, B., Forlani, A., Allemanni, G., Morabito, A., Pistillo, M. P., & Romani, M. (2017) · International Journal of Genomics · doi:10.1155/2017/7639084 · Cited by 167 · see citing works

Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization

Garnier, D., Meehan, B., Kislinger, T., Daniel, P. M., Sinha, A., Abdulkarim, B., Nakano, I., & Rak, J. W. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox142 · Cited by 145 · see citing works

Glycosylation Changes in Brain Cancer

Veillon, L. J., Fakih, C., Abou‐El‐Hassan, H., Kobeissy, F. H., & Mechref, Y. S. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00271 · Cited by 141 · see citing works

ATF3 contributes to brucine-triggered glioma cell ferroptosis via promotion of hydrogen peroxide and iron

Lu, S., Wang, X., He, C., Wang, L., Liang, S.-P., Wang, C., Li, C., Luo, T., Feng, C., Wang, Z.-C., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00700-w · Cited by 142 · see citing works

Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma

Taylor, M. A., Das, B. C., & Ray, S. K. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1480-9 · Cited by 140 · see citing works

Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma

Bastiancich, C., Vanvarenberg, K., Učakar, B., Pitorre, M., Bastiat, G., Lagarce, F., Véronique Préat, A., & Danhier, F. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.054 · Cited by 129 · see citing works

Tumour exosomes from cells harbouring PTPRZ1–MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma

Zeng, A.-L., Yan, W., Liu, Y.-W., Wang, Z., Hu, Q., Nie, E., Xin Min, Z. H. O. U., Li, R., Wang, X.-F., Jiang, T., et al. (2017) · Oncogene · doi:10.1038/onc.2017.134 · Cited by 120 · see citing works

Metallacarboranes on the Road to Anticancer Therapies: Cellular Uptake, DNA Interaction, and Biological Evaluation of Cobaltabisdicarbollide [COSAN] −

Fuentes, I., García‐Mendiola, T., Sato, S., Pita, M., Nakamura, H., Lorenzo, E., Teixidor, F., Marques, F., & Viñas, C. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201803178 · Cited by 121 · see citing works

Nanoparticles: Novel vehicles in treatment of Glioblastoma

Pourgholi, F., Hajivalili, M., Jadidi‐Niaragh, F., Kafil, H. S., & Yousefi, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.12.014 · Cited by 120 · see citing works

Long Non-Coding RNA MALAT1 Decreases the Sensitivity of Resistant Glioblastoma Cell Lines to Temozolomide

Li, H., Yuan, X., Yan, D., Li, D., Guan, F., Yang, D., Wang, H., Liu, X., & Yang, B. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478917 · Cited by 113 · see citing works

LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma

Liu, B., Zhou, J., Wang, C., Chi, Y., Wei, Q., Fu, Z., Lian, C., Huang, Q., Liao, C., Yang, Z., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2540-y · Cited by 113 · see citing works

Deep Learning of Imaging Phenotype and Genotype for Predicting Overall Survival Time of Glioblastoma Patients

Tang, Z., Xu, Y., Jin, L., Aibaidula, A., Lu, J., Jiao, Z., Wu, J., Zhang, H., & Shen, D. G. (2020) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2020.2964310 · Cited by 108 · see citing works

Nucleic acid drug vectors for diagnosis and treatment of brain diseases

Lü, Z., Shen, J., Yang, H. J., Wang, J., Zhao, R., Zhang, T.-L., Guo, J. R., & Zhang, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01298-z · Cited by 108 · see citing works

Corilagin in Cancer: A Critical Evaluation of Anticancer Activities and Molecular Mechanisms

Gupta, A., Singh, A. K., Kumar, R., Ganguly, R., Rana, H. K., Pandey, P. K., Sethi, G., Bishayee, A., & Pandey, A. K. (2019) · Molecules · doi:10.3390/molecules24183399 · Cited by 102 · see citing works

Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8

Berenguer, J., Lagerweij, T., Zhao, X. W., Dusoswa, S. A., van der Stoop, P. P. M., Westerman, B. A., de Gooijer, M. C., Zoetemelk, M., Zomer, A., Crommentuijn, M. H. W., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1446660 · Cited by 99 · see citing works

An Interplay between Senescence, Apoptosis and Autophagy in Glioblastoma Multiforme—Role in Pathogenesis and Therapeutic Perspective

Pawłowska, E., Szczepańska, J., Szatkowska, M., & Błasiak, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030889 · Cited by 98 · see citing works

JNK Pathway in CNS Pathologies

Corrales, T. D. L. R., Losada‐Pérez, M., & Casas‐Tintó, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083883 · Cited by 92 · see citing works

The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response

D’Alessandris, Q. G., Biffoni, M., Martini, M., Runci, D., Buccarelli, M., Cenci, T., Signore, M., Stancato, L. F., Olivi, A., Maria, R. D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now304 · Cited by 86 · see citing works

Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma

Przystal, J. M., Waramit, S., Pranjol, M. Z. I., Yan, W., Chu, G., Chongchai, A., Samarth, G. M., Olaciregui, N. G., Tabatabai, G., Carcaboso, A. M., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201708492 · Cited by 87 · see citing works

Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches

Miranda, A., Blanco‐Prieto, M. J., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.056 · Cited by 84 · see citing works

Galectin-1 inhibitors and their potential therapeutic applications: a patent review

Blanchard, H., Bum‐Erdene, K., Bohari, M. H., & Yu, X. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1163338 · Cited by 84 · see citing works

An Insight into the Increasing Role of LncRNAs in the Pathogenesis of Gliomas

Yan, Y., Xu, Z., Li, Z., Sun, L., & Gong, Z. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00053 · Cited by 78 · see citing works

Vimentin as a potential target for diverse nervous system diseases

Wang, T., Qiu, X., Wu, H., Chen, K., Liu, S., Li, Y., He, T., & Zhao, J. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355744 · Cited by 77 · see citing works

Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options

Gao, H., Xi, Z., Dai, J., Xue, J., Guan, X., Zhao, L., Chen, Z., & Xing, F. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02005-y · Cited by 79 · see citing works

Glioblastoma cells vampirize WNT from neurons and trigger a JNK/MMP signaling loop that enhances glioblastoma progression and neurodegeneration

Portela, M., Venkataramani, V., Fahey-Lozano, N., Seco, E., Losada‐Pérez, M., Winkler, F., & Casas‐Tintó, S. (2019) · PLoS Biology · doi:10.1371/journal.pbio.3000545 · Cited by 76 · see citing works

miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma

Li, Y., Liu, Y., Ren, J. F., Deng, S., Yi, G., Guo, M., Shu, S., Zhao, L., Peng, Y.-P., & Qi, S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2835-3 · Cited by 74 · see citing works

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma

Wang, B., Peng, F., Huang, W., Zhou, J., Zhang, N., Sheng, J., Haruehanroengra, P., He, G., & Han, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.12.013 · Cited by 73 · see citing works

The oxido-metabolic driver ATF4 enhances temozolamide chemo-resistance in human gliomas

Chen, D., Rauh, M., Buchfelder, M., Eyüpoglu, I. Y., & Savaskan, N. E. (2017) · Oncotarget · doi:10.18632/oncotarget.17737 · Cited by 72 · see citing works

Modulation ofMKNK2alternative splicing by splice-switching oligonucleotides as a novel approach for glioblastoma treatment

Mogilevsky, M., Tepper, O., Kumar, S., Mogilevsky, A., Keshet, E., Yavin, E., Heyd, F., & Karni, R. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky921 · Cited by 69 · see citing works

The RNA-Binding Ubiquitin Ligase MEX3A Affects Glioblastoma Tumorigenesis by Inducing Ubiquitylation and Degradation of RIG-I

Bufalieri, F., Caimano, M., Severini, L. L., Basili, I., Paglia, F., Sampirisi, L., Loricchio, E., Petroni, M., Canettieri, G., Santoro, A., et al. (2020) · Cancers · doi:10.3390/cancers12020321 · Cited by 68 · see citing works

β‐asarone inhibited cell growth and promoted autophagy via P53/Bcl‐2/Bclin‐1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells

Wang, N., Zhang, Q., Luo, L., Ning, B., & Fang, Y. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26118 · Cited by 68 · see citing works

Small‐Molecule Kinase‐Inhibitors‐Loaded Boron Cluster as Hybrid Agents for Glioma‐Cell‐Targeting Therapy

Couto, M., Mastandrea, I., Cabrera, M., Cabral, P., Teixidor, F., Cerecetto, H., & Viñas, C. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701965 · Cited by 67 · see citing works

Current Approaches and Challenges in the Molecular Therapeutic Targeting of Glioblastoma

Mooney, J. H., Bernstock, J. D., Ilyas, A., Ibrahim, A. G. A., Yamashita, D., Markert, J. M., & Nakano, I. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.05.205 · Cited by 65 · see citing works

Impact of Galectins in Resistance to Anticancer Therapies

Navarro, P., Martínez‐Bosch, N., Blidner, A. G., & Rabinovich, G. A. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3870 · Cited by 64 · see citing works

Chromatin Remodeling Factor LSH is Upregulated by the LRP6-GSK3β-E2F1 Axis Linking Reversely with Survival in Gliomas

Xiao, D., Huang, J. X., Pan, Y., Li, H. R., Fu, C., Mao, C., Cheng, Y., Shi, Y., Chen, L., Jiang, Y., et al. (2016) · Theranostics · doi:10.7150/thno.17032 · Cited by 62 · see citing works

Green sol–gel synthesis of hydroxyapatite nanoparticles using lemon extract as capping agent and investigation of its anticancer activity against human cancer cell lines (T98, and SHSY5)

Baladi, M., Amiri, M., Mohammadi, P., Mahdi, K. S., Golshani, Z., Razavi, R., & Salavati‐Niasari, M. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104646 · Cited by 60 · see citing works

Gemcitabine and glioblastoma: challenges and current perspectives

Bastiancich, C., Bastiat, G., & Lagarce, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.010 · Cited by 60 · see citing works

Investigating the role of Hedgehog/GLI1 signaling in glioblastoma cell response to temozolomide

Melamed, J. R., Morgan, J. T., Ioele, S. A., Gleghorn, J. P., Sims‐Mourtada, J., & Day, E. S. (2018) · Oncotarget · doi:10.18632/oncotarget.25467 · Cited by 60 · see citing works

Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy

Guan, X., Hasan, M. N., Begum, G., Kohanbash, G., Carney, K. E., Pigott, V. M., Persson, A. I., Castro, M. G., Jia, W., & Sun, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1062-3 · Cited by 60 · see citing works

Glioblastoma multiforme: an updated overview of temozolomide resistance mechanisms and strategies to overcome resistance

Pu, J., Yuan, K., Tao, J., Qin, Y., Li, Y., Fu, J., Zhong, L., Zhou, H., Tang, Z., Li, L., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02567-3 · Cited by 59 · see citing works

Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients

Lin, L., Wang, G., Ming, J., Meng, X., Han, B., Sun, B., Cai, J., & Jiang, C. (2016) · Tumor Biology · doi:10.1007/s13277-016-5462-7 · Cited by 58 · see citing works

TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells

Tian, T., Li, A., Lu, H., Luo, R., Zhang, M., & Li, Z. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.115 · Cited by 58 · see citing works

Molecular and Circulating Biomarkers in Patients with Glioblastoma

Senhaji, N., Houssaini, A. S., Lamrabet, S., Louati, S., & Bennis, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137474 · Cited by 58 · see citing works

Design of temozolomide-loaded proliposomes and lipid crystal nanoparticles with industrial feasible approaches: comparative assessment of drug loading, entrapment efficiency, and stability at plasma pH

Waghule, T., Rapalli, V. K., Singhvi, G., Gorantla, S., Khosa, A., Dubey, S. K., & Saha, R. N. (2020) · Journal of Liposome Research · doi:10.1080/08982104.2020.1748648 · Cited by 57 · see citing works

Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles

Miranda, A., Blanco‐Prieto, M. J., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.049 · Cited by 56 · see citing works

TOPK inhibits autophagy by phosphorylating ULK1 and promotes glioma resistance to TMZ

Lu, H. J., Xiao, J., Ke, C., Ni, X., Xiu, R., Tian, Q., Pan, H., Zou, L., Wang, F., Ma, T., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1805-9 · Cited by 55 · see citing works

Acquired temozolomide resistance in human glioblastoma cell line U251 is caused by mismatch repair deficiency and can be overcome by lomustine

Stritzelberger, J., Distel, L. V., Buslei, R., Fietkau, R., & Putz, F. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1743-x · Cited by 53 · see citing works

Natural products as promising targets in glioblastoma multiforme: a focus on NF-κB signaling pathway

Soukhtanloo, M., Mohtashami, E., Maghrouni, A., Mollazadeh, H., Mousavi, S. H., Roshan, M. K., Tabatabaeizadeh, S., Hosseini, A., Vahedi, M. M., Jalili‐Nik, M., et al. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00081-7 · Cited by 51 · see citing works

FOXO3a protects glioma cells against temozolomide-induced DNA double strand breaks via promotion of BNIP3-mediated mitophagy

He, C. H., Lu, S., Wang, X., Wang, C., Wang, L., Liang, S.-P., Luo, T., Wang, Z.-C., Piao, M., Chi, G., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00663-y · Cited by 51 · see citing works

Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway

Yin, H., & Cui, X. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3575 · Cited by 50 · see citing works

LGALS3 Promotes Treatment Resistance in Glioblastoma and Is Associated with Tumor Risk and Prognosis

Wang, H., Song, X., Huang, Q., Xu, T., Yun, D., Wang, Y., Hu, L., Yan, Y., Chen, H., Li, J., et al. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0638 · Cited by 49 · see citing works

Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment

Hudson, A. L., Parker, N., Khong, P., Parkinson, J., Dwight, T., Ikin, R. J., Zhu, Y., Chen, J., Wheeler, H., & Howell, V. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00314 · Cited by 46 · see citing works

Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma

Rajesh, Y., Biswas, A., Kumar, U., Das, S., Banerjee, I., Banik, P., Bharti, R., Nayak, S., Ghosh, S. K., & Mandal, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.025 · Cited by 45 · see citing works

Identification of SEC61G as a Novel Prognostic Marker for Predicting Survival and Response to Therapies in Patients with Glioblastoma

Liu, B., Liu, J., Liao, Y., Chen, J., Zhang, Z., Zhao, J., Liu, K., Huang, H., Cao, H., & Cheng, Q. (2019) · Medical Science Monitor · doi:10.12659/msm.916648 · Cited by 46 · see citing works

Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF

Wang, C., He, C. H., Lu, S., Wang, X., Wang, L., Liang, S.-P., Wang, X., Piao, M., Cui, J., Chi, G., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02866-3 · Cited by 46 · see citing works

FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways

Yihan, W., Li, D., Bao, S., Wang, M., Yun, Y.-L., & Zhu, R. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.051 · Cited by 45 · see citing works

Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH ‐mutated gliomas revealed by mass spectrometry imaging

Kampa, J. M., Kellner, U., Marsching, C., Guevara, C. R., Knappe, U. J., Sahin, M., Giampà, M., Niehaus, K., & Bednarz, H. (2020) · Neuropathology · doi:10.1111/neup.12671 · Cited by 45 · see citing works

Connexin 43 confers chemoresistance through activating PI3K

Pridham, K. J., Shah, F., Hutchings, K. R., Sheng, K. L., Guo, S., Liu, M., Kanabur, P., Lamouille, S., Lewis, G., Morales, M., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00378-7 · Cited by 43 · see citing works

Exploring ncRNA-mediated regulation of EGFR signalling in glioblastoma: From mechanisms to therapeutics

Thapa, R., Afzal, M., Goyal, A., Gupta, G., Bhat, A. A., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Shahwan, M. J., Kukreti, N., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122613 · Cited by 44 · see citing works

Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide

Forte, I. M., Indovina, P., Iannuzzi, C. A., Cirillo, D., Marzo, D. D., Barone, D., Capone, F., Pentimalli, F., & Giordano, A. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4788 · Cited by 42 · see citing works

Gold-based nanomaterials for the treatment of brain cancer

Tu, L., Luo, Z., Wu, Y., Huo, S., & Liang, X. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0524 · Cited by 43 · see citing works

LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma

He, X., Sheng, J., Yu, W., Wang, K., Zhu, S., & Liu, Q. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00898-z · Cited by 42 · see citing works

Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin αv in Glioblastoma Cells

Yu, Q., Xiao, W., Sun, S., Sohrabi, A., Liang, J., & Seidlits, S. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.616580 · Cited by 42 · see citing works

Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy

Chou, S., Yen, S., Huang, C., & Huang, E. (2018) · BMC Cancer · doi:10.1186/s12885-018-4025-2 · Cited by 40 · see citing works

A biodegradable nanocapsule for through-skull NIR-II fluorescence imaging/magnetic resonance imaging and selectively enhanced radio-chemotherapy for orthotopic glioma

Yin, N., Wang, Y., Cao, Y., Huang, Y., Jin, L., Zhang, S., Liu, J., Zhang, T., Lv, Z., Liu, Y., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101619 · Cited by 40 · see citing works

Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization

Hinrichs, C. N., Ingargiola, M., Käubler, T., Löck, S., Temme, A., Köhn‐Luque, A., Deutsch, A., Vovk, O. I., Stasyk, O. V., & Kunz‐Schughart, L. A. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0807 · Cited by 39 · see citing works

Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair

Kim, G. W., Lee, D. H., Yeon, S.-K., Jeon, Y. H., Yoo, J. H., Lee, S. W., & Kwon, S. H. (2019) · Anticancer Research · doi:10.21873/anticanres.13888 · Cited by 39 · see citing works

CD90low glioma-associated mesenchymal stromal/stem cells promote temozolomide resistance by activating FOXS1-mediated epithelial-mesenchymal transition in glioma cells

Xue, B., Xiang, W., Zhang, Q., Wang, H., Zhou, Y., Tian, H., Abdelmaksou, A., Xue, J., Sun, M., Yi, D., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02458-8 · Cited by 39 · see citing works

Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma

Pena, E. S., Graham-Gurysh, E. G., Bachelder, E. M., & Ainslie, K. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313160 · Cited by 39 · see citing works

Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage

Shen, C. J., Kummerlowe, M. N., Redmond, K. J., Martínez-Gutiérrez, J. C., Usama, S. M., Holdhoff, M., Grossman, S. A., Laterra, J., Strowd, R. E., III, & Kleinberg, L. R. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.06.005 · Cited by 38 · see citing works

YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway

Tong, H., Zhao, K., Zhang, J., Zhu, J., & Xiao, J. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s185514 · Cited by 37 · see citing works

LINC00470 promotes tumour proliferation and invasion, and attenuates chemosensitivity through the LINC00470/miR‐134/Myc/ABCC1 axis in glioma

Wu, C., Su, J., Long, W., Qin, C., Wang, X., Xiao, K., Yang, L., Xiao, Q., Wang, J., Pan, Y., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15846 · Cited by 38 · see citing works

The multifaceted PDCD10/CCM3 gene

Valentino, M., Dejana, E., & Malinverno, M. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.12.008 · Cited by 38 · see citing works

Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity

Marwah, R., Xing, D. T., Squire, T., Soon, Y. Y., Gan, H. K., & Ng, S. P. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04441-0 · Cited by 36 · see citing works

Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme

Senbabaoglu, F., Cingöz, A., Kaya-Aksoy, E., Kazancioglu, S., Lack, N. A., Açılan, C., & Onder, T. B. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1167292 · Cited by 35 · see citing works

Drug resistance in glioblastoma and cytotoxicity of seaweed compounds, alone and in combination with anticancer drugs: A mini review

Ferreira, J. S. P. D. M., Ramos, A. A., Almeida, T., Azqueta, A., & Rocha, E. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.04.062 · Cited by 35 · see citing works

Anti-cancer Effects of Fucoxanthin on Human Glioblastoma Cell Line

Lopes, F. G., de Oliveira, K. A., Lopes, R. G., Poluceno, G. G., Simioni, C., Pescador, G. D. S., Bauer, C. M., Maraschin, M., Dérner, R. B., Garcez, R. C., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14703 · Cited by 35 · see citing works

A novel polysaccharide derived from algae extract induces apoptosis and cell cycle arrest in human gastric carcinoma MKN45 cells via ROS/JNK signaling pathway

Xie, P., Fujii, I., Zhao, J.-E., Shinohara, M., & Matsukura, M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3658 · Cited by 35 · see citing works

Sulforaphane induces apoptosis and inhibits invasion in U251MG glioblastoma cells

Zhang, Z., Li, C., Shang, L., Zhang, Y., Zou, R., Zhan, Y., & Bi, B. (2016) · SpringerPlus · doi:10.1186/s40064-016-1910-5 · Cited by 34 · see citing works

LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway

Zhong, C., Chen, Y., Tao, B., Peng, L., Peng, T., Yang, X., Xia, X., & Chen, L. (2018) · BMC Cancer · doi:10.1186/s12885-018-4649-2 · Cited by 33 · see citing works

TFR2 regulates ferroptosis and enhances temozolomide chemo-sensitization in gliomas

Tong, S., Yu, H., Xu, Y., Sun, Q., Ye, L., Cai, J., Ye, Z., Chen, Q., & Tian, D. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113474 · Cited by 33 · see citing works

Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia‐inducible factor 1α/hedgehog pathway under hypoxia

Wei, M., Ma, R., Huang, S., Liao, Y., Ding, Y., Li, Z., Guo, Q., Tan, R. X., Zhang, L., & Zhao, L. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28361 · Cited by 33 · see citing works

Cytotoxic Effects of Chlorophyllides in Ethanol Crude Extracts from Plant Leaves

Wang, Y.-T., Yang, C.-H., Huang, T.-Y., Tai, M., Sie, R.-H., & Shaw, J. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/9494328 · Cited by 32 · see citing works

Chronic exposure of human glioblastoma tumors to low concentrations of a pesticide mixture induced multidrug resistance against chemotherapy agents

Doğanlar, O., Doğanlar, Z. B., Kurtdere, A. K., Chasan, T., & Ok, E. S. (2020) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2020.110940 · Cited by 32 · see citing works

IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway

Li, K., Ouyang, L., He, M., Luo, M., Cai, W., Tu, Y., Pi, R., & Liu, A. (2017) · Oncotarget · doi:10.18632/oncotarget.15868 · Cited by 31 · see citing works

MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor

Chen, Y., Li, R. Q., Pan, M., Shi, Z., Yan, W., Liu, N., You, Y., Zhang, J., & Wang, X. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2463-3 · Cited by 31 · see citing works

Insulin signaling mediates neurodegeneration in glioma

Jarabo, P., de Pablo, C., Herranz, H., Martín, F. A., & Casas‐Tintó, S. (2021) · Life Science Alliance · doi:10.26508/lsa.202000693 · Cited by 31 · see citing works

TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1

Wei, J., Wang, L., Zhang, Y., Sun, T., Zhang, C., Hu, Z., Zhou, L., Liu, X., Wan, J., & Ma, L. (2023) · Oncogene · doi:10.1038/s41388-023-02717-3 · Cited by 31 · see citing works

DHFR/TYMS are positive regulators of glioma cell growth and modulate chemo-sensitivity to temozolomide

Zhao, M., Tan, B., Dai, X., Shao, Y., He, Q., Yang, B., Wang, J., & Weng, Q. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172665 · Cited by 31 · see citing works

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas

Cai, H., Liu, A.-S., Zhang, M.-J., Liu, H.-J., Meng, X., Qian, H.-P., & Wan, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00669 · Cited by 30 · see citing works

Anticancer Potential of Temozolomide-Loaded Eudragit-Chitosan Coated Selenium Nanoparticles: In Vitro Evaluation of Cytotoxicity, Apoptosis and Gene Regulation

Mazarei, M., Arvejeh, P. M., Mozafari, M. R., Khosravian, P., & Ghasemi, S. (2021) · Nanomaterials · doi:10.3390/nano11071704 · Cited by 30 · see citing works

Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems

Petrenko, D. А., Chubarev, V. N., Syzrantsev, N., Ismail, N. M., Меркулов, В. А., Sologova, S. S., Grigorevskikh, E., Smolyarchuk, Е. А., & Alyautdin, R. N. (2022) · Molecules · doi:10.3390/molecules27113507 · Cited by 30 · see citing works

Research progress of drug resistance mechanisms to temozolomide in glioblastoma: A narrative review

Lu, A. (2022) · Glioma · doi:10.4103/glioma.glioma_24_22 · Cited by 2 · see citing works

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 408 · see citing works

Research Progress on Temozolomide Resistance Mechanisms and Strategies to Overcome Resistance

(2026) · Journal of Chemical Biological and Physical Sciences · doi:10.24214/jcbps.a.16.1.09816

Novel strategies to overcome chemoresistance in human glioblastoma

Tang, Q., Ren, T., Bai, P., Wang, X., Zhao, L., Zhong, R., & Sun, G. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116588 · Cited by 23 · see citing works

Molecular mechanisms in temozolomide-resistant glioblastoma

Lee, S. Y., & Kitange, G. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00029-4 · Cited by 1 · see citing works